Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2221268 | 1.00 | ADORA2A (0.61) | ADORA2AADORA1ADORA3ADORA2BSLC29A1 | |
| SCHEMBL2220562 | 0.88 | SLC29A1 (0.65) | ADORA2AADORA1ADORA3ADORA2BSLC29A1 | |
| SCHEMBL2220567 | 0.88 | SLC29A1 (0.65) | ADORA2AADORA1ADORA3ADORA2BSLC29A1 | |
| SCHEMBL12803495 | 0.83 | ADORA2A (0.59) | ADORA2AADORA1ADORA3ADORA2BSLC29A1 | |
| SCHEMBL12803497 | 0.83 | ADORA2A (0.59) | ADORA2AADORA1ADORA3ADORA2BSLC29A1 | |
| SCHEMBL2218916 | 0.83 | SLC29A1 (0.54) | ADORA2AADORA1ADORA3ADORA2BSLC29A1 | |
| SCHEMBL2218911 | 0.83 | SLC29A1 (0.54) | ADORA2AADORA1ADORA3ADORA2BSLC29A1 | |
| SCHEMBL2220833 | 0.82 | ADORA1 (0.58) | ADORA2AADORA1ADORA3ADORA2BSLC29A1 | |
| SCHEMBL2220825 | 0.82 | ADORA1 (0.58) | ADORA2AADORA1ADORA3ADORA2BSLC29A1 | |
| SCHEMBL2221717 | 0.81 | ADORA2A (0.60) | ADORA2AADORA1ADORA3ADORA2BSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877439-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2014-11-04 | — | — | US | claimed |
| US-9512426-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150132761-A1 | METHOD FOR RAPIDLY EVALUATING PERFORMANCE OF SHORT INTERFERING RNA WITH NOVEL CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-05-14 | — | — | US | disclosed |
| US-8877439-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2513337-A1 | A METHOD FOR RAPIDLY EVALUATING PERFORMANCE OF SHORT INTERFERING RNA WITH NOVEL CHEMICAL MODIFICATIONS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | BANK OF AMERICA, N.A. | 2012-10-04 | — | — | US | disclosed |
| WO-2011084345-A1 | A METHOD FOR RAPIDLY EVALUATING PERFORMANCE OF SHORT INTERFERING RNA WITH NOVEL CHEMICAL MODIFICATIONS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | NSUN2, NSUN3, SNRPE | ADORA2A 615/4885ADORA1 1080/4885ADORA3 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.